Introduction
============

Cervical cancer remains a major health issue in Belgium with 4070 in situ cancers and 468 invasive cervical cancers in the 2013-2014 period ([@B2]). Primary and secondary prevention, however, has the potential to make cervical cancer a historical disease ([@B37]; [@B38]).

The primary prevention is the prophylactic HPV vaccination. At present, there are three prophylactic HPV vaccines: Gardasil, Cervarix and Gardasil 9. The school-based vaccination program in the Flemish part of Belgium has a coverage of 91% and in the French Community the coverage is around 36% ([@B45]). Recent long-term data in countries with a high vaccination coverage (\> 80%) showed a reduction in targeted HPV infections with 90% and high-grade lesions with 85% ([@B8]; [@B15]). Within 20 to 30 years it is expected that the incidence of cervical cancer will decrease by 70 to 80% ([@B41]). The 9 valent HPV vaccine, which was introduced last year and is reimbursed for girls between 12 -- 19 years old, is expected to increase the figures by 14 -- 18%.

We still have to continue cervical cancer screening because not all women are vaccinated and the vaccine does not protect against all types of cervical cancer. Cervical cancer screening should shift from primary cytology to primary HPV screening ([@B40]). Ideally, diagnostic cytology should be performed. This would reduce the incidence of cervical cancer by 36% and the annual mortality by 40% ([@B43]; [@B44]). Despite the fact that we believe that almost all cervical cancers are due to a HPV infection, we do not always find HPV in women with cervical cancer. The recently published annual cervical cancer screenings report in Belgium suggested that 15% of cervical cancers were HPV negative ([@B2]). This high figure created confusion on whether or not primary HPV screening is the best way forward. It is important to realize that primary HPV screening will, like every cancer screenings test, not detect all precancers and cancers. The present article will address the issue of HPV negative cancers and give a possible explanation.

HPV negative cancers
====================

The Belgian cancer register looked at all the performed HPV tests before or at the moment of cancer diagnosis ([@B2]). HPV results after the diagnosis (incidence date) were not included. A tumor was considered HPV positive if at least 1 positive HPV result was registered, regardless of the timespan between the HPV test and the incidence date and irrespectively of previous HPV texts ([@B2]). Only 29% (136 / 468) of invasive cervical cancers (time period 2013- 2014) had some kind of HPV test. Twenty out of 136 (14,7%) of individuals tested had a HPV negative tumor. These figures sound interesting, but they are not conclusive for the entire female population. In modern communication this would probably be called "Fake News". In Belgium there is only a reimbursement for HPV analysis in case of ASCUS. It is therefore unclear why these women had a HPV analysis. For instance: "Were these women screened as part of a study?" or "Were there other reasons to perform a HPV test in this group?"

From a test point of view, there are multiple questions regarding this representation. For instance, it is unclear which test was used and if all these analyses were done on a smear or on a tissue sample. It is likely that a mix of different HPV tests was used. Also, it remains unknown if these tests were validated. The figure of 14,7% HPV negative cervical cancer mentioned in the Annual Report (period 2013-2014) should be compared with previous data form our country and worldwide ([@B2]). The first study that reported HPV data in Belgian women with cervical cancer looked at a period before the year 2000. In this study there were 13% HPV "negative" cancers ([@B36]). In an additional study looking at the period 2001-2008 the reported number of HPV negative tumors was 7,1% ([@B42]). Looking at HPV type-specific prevalence data published from 1990 to 2010 (243 studies and 30,848 women with an invasive cervical cancer) a similar decrease in HPV negative tumors was also seen ([@B20]). In this meta-analysis the HPV positivity for the period 1990-1999, 2000-2005 and 2006-2010 was, respectively, 85,9%, 87,9% and 92,9% ([@B20]). The decrease in HPV negative cancers is likely to reflect improvements in the HPV detection methods. The exclusion of misclassified disease by a careful central histopathological review of all samples also reduces the number of HPV negative tumors (Tjalma et al., 2012). Worldwide it is estimated that the percentage for HPV negative tumors fluctuates between 7 -- 11% ([@B6]; [@B10]; [@B12]; [@B13]; [@B20]; [@B26]).

Explanations for HPV negative cancers
=====================================

Cervical cancers independent of HR HPV
--------------------------------------

Invasive cervical cancer (ICC) can be divided in three groups. The first group are squamous cervical cancers (SCC) and they account for 75-90% of ICCs ([@B34]). The second group are adenocarcinomas (ADC) and adenosquamous cell carcinomas (ASC) which account for 10-25% of all ICCs ([@B34]). The ASC has features of both SCC and ADC, but are often included in ADC classification because of their relatively small numbers. The last group is a collection of rare cancers and includes melanoma, sarcoma, lymphoma, neuroendocrine tumors and cancers of unspecified histology ([@B34]; [@B46]).

There are several reasons for HPV negative cervical cancers ([Table I](#t001){ref-type="table"}). First of all, there are cervical cancers independent from HPV infection, these are the true HPV negative cancers. For a squamous cancer to be HPV negative is very uncommon (almost 100% HPV positive) ([@B27]). Among adenosquamous cancers the HPV positivity is almost 86% ([@B11]). In situ adenocarcinomas are almost always high risk HPV positive ([@B27]). The prevalence of HPV among adenocarcinoma varies between the subtypes. ADCs can be divided in a group of subtypes which have a high HPV prevalence and in a group with low HPV prevalence ([Table II](#t002){ref-type="table"}).
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###### 

HPV prevalence in adenocarcinoma ([@B11]; [@B27]; [@B29]; [@B33]) ^Inc.\ on\ behalf\ of\ UICC.Cervical\ glandular\ neoplasias\ (CGN^

  -------------------- ------------------------------------ ----------------- -----
  ADC                  \% of ADC                            \% HPV positive   
  Usual type           75                                   80 - 100          
  Intestinal           8                                    83 - 100          
  Villoglandular^\*^   3-6                                  100               
  Signet ring cell     rare                                 100               
  Endometrioid^\*\*^   rare                                 100               
                       \- From SCJ                                            100
                       \- From upper cervix/lower uterine                     0
  Serous               very rare                            30                
  Clear cell           2-7                                  28                
  Gastric type         unknown                              0                 
  Mesonephric          rare                                 0                 
  -------------------- ------------------------------------ ----------------- -----

\*villogladular ADC is a well differentiated variant of endocervical, endometrioid, or intestinal ADC.

\*\* Endometrioid ADC is a rare variant developing from either tuboendometrioid metaplasia or endometriosis. The can be divided in tumors originating from the squamous columnar junction zone or from the upper part of the endocervix and lower uterine segment.

Subtypes with a high prevalence of HPV are the usual type, intestinal, villoglandular, signet-ring cell and the endometrioid ADCs which originate from the cervical squamous columnar junction zone. Together they account for more than 90% of all ADCs. Subtypes with a low HPV prevalence are serous and clear cell ADCs. Due to the rareness of these subtypes only a low number of cases are tested. When comparing the different small studies, you notice that the HPV positivity figure vary, which is confusing. Subtypes which are typically HPV negative (unrelated to HPV) are the gastric type, the mesonephric type and the endometrioid ADC from the upper part of the endocervix and lower uterine segment. These subtypes are however rare. The minimal deviation adenocarcinoma of mucinous type is considered a well-differentiated form of gastric ADC ([@B18]; [@B27]). The incidence of the gastric type is actually unknown as it is a new histopathologic entity since 2014 ([@B18]; [@B27]). The pathogenesis in the group of cervical cancers, with low or no HPV prevalence is unrelated or independent of HPV.

Support for these HPV independent pathway(s) are the fact that these types have been linked to mutations. In clear cell ADC the PI3K-AKT pathway could be involved as in 50% of cases a positive p-AKT and p-mTOR immunostaining is observed ([@B47]; [@B27]). In older patients suffering from this subtype of ADC there is a loss of PTEN expression in 50% of cases and an increased expression of EGFR and HER2 in 75% and 50% of the cases, respectively ([@B47]; [@B27]). The gastric types are associated to somatic and germ line (Peutz-Jeghers syndrome) STK11 mutations and TP53 mutations ([@B29]). In mesonephric ADCs 81% had a KRAS or NRAS mutations, 62% had an ARID1A or ARID1B or SMARCA4 mutations and 0% had a PIK3CA or PTEN mutations ([@B22]; [@B27]). Mesonephric ADC are characterized by molecular alterations that differ from common variants of cervical adenocarcinoma, which harbor KRAS/NRAS mutations in 7% of cases ([@B22]). A treatment option for the mesonephric ADC could therefore be inhibitors of the RAS/ MAPK pathway.

Cervical cancers which lose expression of HPV
---------------------------------------------

Another group of tumors which can be regarded as false negative, are those tumors that lose HPV. More and more reports are describing the molecular features of cervical cancer ([@B1]; [@B25]; [@B4]; [@B5]). There is a subset of tumors, which no longer express HPV E6/E7 oncogenes (HPV-inactive) ([@B4]). These HPV-inactive tumors have a global decrease in DNA methylation and an increased WNT/ β-catenin and Sonic Hedgehog signaling ([@B4]). The somatic mutation landscapes between the HPV active and inactive tumors is significantly different. The HPV- inactive tumors have non-synonymous somatic mutations (specifically targeting TP53, ARID, WNT, and PI3K pathways) and the HPV-active tumors have only few somatic mutations. These altered pathways in HPV inactive cancers open the option for targeted therapies ([@B4]). More research is needed to explore these treatment options. Treatment strategies focusing on WNT, PI3K, or TP53 mutations may be effective against HPV-inactive tumors and may improve the survival rate in patients suffering from these cervical cancers ([@B4]).

Cervical cancer due to non-high risk HPV
----------------------------------------

To our knowledge, only one publication links cervical cancer and low risk HPV 6 ([@B9]). Whether this is the cause or an accidental infection remains unknown. Only a few limited reports link non-high risk HPV types to cervical cancer ([@B51]; [@B26]). These estimate that about 1‒2% of primary cervical cancers are associated with non- high risk HPV ([@B26]). Currently used and validated HPV screening tests are designed to detect high risk HPV only. Therefore, the later fail to detect non-high risk HPV and subsequently their associated cancers.

Misclassified cancers
---------------------

Additionally, a group of misclassified endometrial cancers (direct extension) and metastasis from other primary tumors which test HPV negative should be considered. Central pathology reviews in major studies has reclassified multiple cancers (Tjalma et al., 2012; [@B28]; [@B11]). Unfortunately, not all published studies have had a centralized pathology review. In a recent study among HPV negative adenocarcinoma it was not possible in more than 50 % of the cases to determine the origin of the tumor (cervical vs uterine) based upon histological features ([@B12]). To differentiate between a primary endometrial adenocarcinoma and a primary adenocarcinoma of the (endo) cervix, based on histological features alone, is difficult if not impossible in some cases. HPV testing together with immunostaining of tumor and stromal cells, can be very useful for this distinction ([@B27]). The combination of ER-; PR-; vimentin -; p16 diffuse +; CEA +; CD 10-; CD 34+ and HPV + is suggestive for an endocervical adenocarcinoma, while the combination of ER+; PR+; vimentin +; p16 patchy +; CEA -; CD 10+; CD 34- and HPV -- support the diagnosis of uterine adenocarcinoma. Age is also a helpful indicator. The triad, older age, HPV negative and non-squamous cancer is the signature of an uterine cancer and not of a cervical cancer.

Metastasis in an extra genital site to the cervix is a rare event ([@B14]). An old study revealed that only 3.7% of the metastatic female genital neoplasms involved the cervix ([@B21]).

HPV testing
-----------

There is a difference in HPV prevalence between squamous cancers and ADC. This is due to the fact that some ADC subtypes have low or no HPV positivity. But, undoubtedly it also involves the fact that the HPV DNA load in an ADC is much lower, making its detection a difficult challenge ([@B27]). In contrast to a squamous epithelium, a glandular epithelium does not support a productive HPV infection. Thus, in cases of squamous carcinoma this may lead to a highly replicated episomal HPV DNA copy numbers along with integrated virus in the infected cells. In the glandular epithelium there is no accumulation of replicated episomal HPV DNA in the infected glandular cell and only low copy numbers of HPV DNA are integrated and only a low copy number of HPV DNA present integrated into the cell genome ([@B28]). This is due to highly sensitive PCR primers identifying more and different HPV infections ([@B27]).

The first reason for false negative tests are sampling errors. For instance, inadequate cellularity (a cancer with necrosis and/or inflammation is often false negative), obscuring blood or lubricants, inflammation, fixation or cytolysis may result in false negatives. Thus, multiple reasons for questioning the representativeness of HPV testing in currently published studies exist. Some of these studies tested HPV on old (if not very old) stored HPV material, rendering impossible to determine if this material could be representative. A retrospective study showed that tumors from older patients and tumour samples stored for a longer time had a lower HPV prevalence ([@B28]). Samples stored for more than 30 years have a significantly lower HPV detection rate ([@B28]). The impact is higher in adenocarcinomas than in squamous carcinomas. Other important feature to be considered is the time between excision, fixation and the type of fixing fluid used. In a retrospective study, the use of non-buffered formalin add in different fixation protocols was a significant factor for a decreased detection of HPV ([@B28]). In the reported studies, HPV was sometimes tested on archived tissue, fresh-frozen tissue or in liquid biopsy samples. It is assumed that the outcome of these HPV tests, regardless of the type of biopsy, is comparable. However, this is not true. A study revealed that for different adenocarcinomas, HPV positivity in freshly frozen tissue was 14.3% higher than the HPV positivity found in paraffin embedded tissue (the difference was not statistically significant) ([@B24]). The same study showed that for squamous carcinoma the HPV positivity in paraffin embedded tissue was 1.6% higher than in freshly frozen tissue (the difference was not statistically significant)([@B24]). In these studies different HPV tests were used and not all HPV tests were validated. It has to be underlined that all HPV tests are different. For instance, the global difference between HPV 16 and HPV 18 tested by L1 HPV test and E6/E7 HPV test is 91.7% and 72.1%, respectively. This means that 8.3% of HPV 16 and 27.9% of HPV 18 are missed by the L1 HPV test ([@B39]). Clinicians are generally not aware that there is a huge difference among HPV tests ([@B39]). In the era of highly effective prophylactic HPV vaccines, it will become important to test for rare HPV types.

It is very likely that false negative results arise due to way tissues were collected, stored and the used HPV test(s). In order to reduce the number of false negative results, it is necessary to standardize an operating procedure (SOP) for tissue collection and HPV testing. The used HPV tests should be validated and have a very high sensitivity. Special attention to the minimal viral load cutoff should be given, because low level persistent HPV infections exist ([@B49]). Laboratories performing HPV testing should be accredited by authorized accreditation bodies and in compliance with international standards ([@B48]).

When a cervical tumor tests negative for HPV, the clinician should have two considerations. First, "could this be a secondary malignancy, either by direct grow or metastasis?". In some clinical settings almost 68% of negative cervical cancers appeared to be misdiagnosed primary cervical cancers ([@B26]). Second, "should the sample be re-tested with a different HPV test?". A HPV-positive result can be explained either by the failure of the initial test procedure to detect high-risk HPV subtypes or by infection with other HPV subtypes, not identified by a standard HPV test ([@B26]). This approach will reduce the number of mistreatments.

Screening
---------

The sensitivity in cytology screening ranges between 50 to 70%. This means that 50 to 30% of abnormal lesions are missed. The sensitivity when testing for DNA on high risk HPV in RCTs (Randomized Controlled Trials) is more than 90% ([@B31]; [@B40]), meaning that less than 10% will be missed. The RCTs showed that in the first screening round more high grade lesions were detected with HPV compared to cytology alone. In the following screening rounds no cervical cancer was found in the HPV arm but only in the cytology arm ([@B7]; [@B17]; [@B23]; [@B30]; [@B32], [@B31]; [@B40]; [@B50]). The end result was a (significant) reduction of cervical cancer in the HPV arm compared to the cytology arm. Worldwide, several countries such as Australia, the UK and the Netherlands, have already switched to primary HPV screening. A large number of countries are considering this transition. Screening with HPV testing is superior to screening by cytology alone. When you compare the different screening methods you will come to the following predictions: no screening will give 8.34 deaths per 1000 women, cytology screening every 3 years will give 0.76 death per 1000 women, primary HR HPV testing or co-testing every 5 years starting at the age of 30 years will give respectively 0.29 and 0.30 cervical cancer deaths per 1000 women ([@B16]; [@B19]). All screening methods however will miss cancers. The question is how many?

There is a group of cancers which has a false diagnosis and group of cervical cancers which was missed (false negative) due to the test which was used, not representative sample, no endocervical cells, low viral load, or because of a small amount of DNA. Retrospective analyses without surgical staging overestimate the proportion of HPV negative cervical cancers ([@B26]). This number should decrease due to the quality control and the improvement of HPV tests.

There is, however, a very small proportion of mainly rare adenocarcinomas which are HPV negative (true negative). A recent study which used next-generation sequencing to characterize primary cervical cancers, found that only 5% of cervical cancers were HPV-negative ([@B5]). HPV vaccination and primary HPV screening will not prevent or detect these tumors. The cytological accuracy for detecting these lesions remains unknown. These tumors have another pathogenesis. Additional investigations regarding their signaling pathways is needed. This could allow the identification of specific molecular tests, for early detection of these rare tumors. HPV inactive tumors have gene expression, DNA methylation and somatic mutation signatures which are different from HPV- active tumors, and similar to those from other viral- independent cancers ([@B4]). The latter opens the possibility for specific targeted therapies which may lead to better survival rates. Finally, the incidence of HPV negative tumors does not inform about the performance of primary HPV screening. Data from randomized controlled trials are very clear: If a woman has a normal cytology and no HPV infection or normal cytology and HPV infection, then, her chances of developing a CIN3 + lesion after 5 years is 0,18% and 6,11%, respectively ([@B3]).

Primary HPV screening with dual-stain cytology in Belgium would reduce the incidence of cervical cancer by 36% and the annual cervical mortality by 40% ([@B43]; [@B44]). We need to improve the screening as we are entering an era of HPV vaccinated women who will get screened. Even though HPV negative cancers could be miss- reported, HPV screening, preferable with triage markers, remain superior to cytology.

Finally, the fact that there are HPV negative cancers should not undermine all idea's regarding primary HPV screening.
